Saltar al contenido
Merck

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

Cancer cell (2002-07-19)
Louise M Kelly, Jin-Chen Yu, Christina L Boulton, Mutiah Apatira, Jason Li, Carol M Sullivan, Ifor Williams, Sonia M Amaral, David P Curley, Nicole Duclos, Donna Neuberg, Robert M Scarborough, Anjali Pandey, Stanley Hollenbach, Keith Abe, Nathalie A Lokker, D Gary Gilliland, Neill A Giese
RESUMEN

Up to 30% of acute myelogenous leukemia (AML) patients harbor an activating internal tandem duplication (ITD) within the juxtamembrane domain of the FLT3 receptor, suggesting that it may be a target for kinase inhibitor therapy. For this purpose we have developed CT53518, a potent antagonist that inhibits FLT3, platelet-derived growth factor receptor (PDGFR), and c-Kit (IC(50) approximately 200 nM), while other tyrosine or serine/threonine kinases were not significantly inhibited. In Ba/F3 cells expressing different FLT3-ITD mutants, CT53518 inhibited IL-3-independent cell growth and FLT3-ITD autophosphorylation with an IC(50) of 10-100 nM. In human FLT3-ITD-positive AML cell lines, CT53518 induced apoptosis and inhibited FLT3-ITD phosphorylation, cellular proliferation, and signaling through the MAP kinase and PI3 kinase pathways. Therapeutic efficacy of CT53518 was demonstrated both in a nude mouse model and in a murine bone marrow transplant model of FLT3-ITD-induced disease.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Tandutinib hydrochloride, ≥98% (HPLC)